| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
68,788,000 |
| Market
Cap: |
2.23(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$14.19 - $52.31 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Arvinas is a biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies to degrade disease-causing proteins. Co. is developing ARV-110, a proteolysis targeting chimeras (PROTAC) targeted protein degrader targeting the androgen receptor protein for the treatment of men with metastatic castration-resistant prostate cancer. Co. is also developing ARV-471, a PROTAC targeted protein degrader targeting the estrogen receptor protein, or ER, for the treatment of patients with locally advanced or metastatic ER positive / HER2 negative breast cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
10,298 |
10,298 |
11,622 |
21,554 |
| Total Sell Value |
$484,521 |
$484,521 |
$516,810 |
$859,747 |
| Total People Sold |
4 |
4 |
4 |
4 |
| Total Sell Transactions |
4 |
4 |
5 |
9 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Berkowitz Noah |
Chief Medical Officer |
• – – |
2024-03-18 |
4 |
A |
$0.00 |
$0 |
D/D |
63,452 |
63,452 |
|
- |
|
| Teel Randy |
Int. Chief Financial OfficerOf |
• – – |
2024-02-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
46,041 |
|
-31% |
|
| Taylor Ian |
Chief Scientific Officer |
• – – |
2024-02-23 |
4 |
S |
$47.05 |
$80,032 |
D/D |
(1,701) |
147,522 |
|
33% |
|
| Taylor Ian |
Chief Scientific Officer |
• – – |
2024-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
39,250 |
149,223 |
|
- |
|
| Peck Ronald |
Chief Medical Officer |
• – – |
2024-02-23 |
4 |
S |
$47.05 |
$79,938 |
D/D |
(1,699) |
67,516 |
|
33% |
|
| Peck Ronald |
Chief Medical Officer |
• – – |
2024-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
39,250 |
69,215 |
|
- |
|
| Houston John G |
President and CEO |
• • – |
2024-02-23 |
4 |
S |
$47.05 |
$244,472 |
D/D |
(5,196) |
1,036,681 |
|
33% |
|
| Houston John G |
President and CEO |
• • – |
2024-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
124,450 |
1,041,877 |
|
- |
|
| Loomis David K |
Chief Accounting Officer |
• – – |
2024-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
5,750 |
8,500 |
|
- |
|
| Cassidy Sean A |
Chief Financial Officer |
• – – |
2024-02-23 |
4 |
S |
$47.05 |
$80,079 |
D/D |
(1,702) |
181,916 |
|
33% |
|
| Taylor Ian |
Chief Scientific Officer |
• – – |
2024-01-04 |
4 |
OE |
$16.00 |
$132,032 |
D/D |
8,252 |
109,973 |
|
- |
|
| Peck Ronald |
Chief Medical Officer |
• – – |
2023-08-11 |
4 |
S |
$24.39 |
$32,289 |
D/D |
(1,324) |
29,965 |
|
-52% |
|
| Peck Ronald |
Chief Medical Officer |
• – – |
2023-08-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,010 |
31,289 |
|
- |
|
| Houston John G |
President and CEO |
• • – |
2023-03-01 |
4 |
S |
$29.53 |
$173,577 |
D/D |
(5,878) |
917,427 |
|
25% |
|
| Houston John G |
President and CEO |
• • – |
2023-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,510 |
923,305 |
|
- |
|
| Cassidy Sean A |
Chief Financial Officer |
• – – |
2023-03-01 |
4 |
S |
$29.53 |
$51,530 |
D/D |
(1,745) |
183,618 |
|
25% |
|
| Cassidy Sean A |
Chief Financial Officer |
• – – |
2023-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,791 |
185,363 |
|
- |
|
| Taylor Ian |
Chief Scientific Officer |
• – – |
2023-03-01 |
4 |
S |
$29.53 |
$31,036 |
D/D |
(1,051) |
101,721 |
|
25% |
|
| Taylor Ian |
Chief Scientific Officer |
• – – |
2023-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,685 |
102,772 |
|
- |
|
| Houston John G |
President and CEO |
• • – |
2023-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
61,975 |
905,795 |
|
- |
|
| Peck Ronald |
Chief Medical Officer |
• – – |
2023-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
19,125 |
27,279 |
|
- |
|
| Taylor Ian |
Chief Scientific Officer |
• – – |
2023-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
19,125 |
100,087 |
|
- |
|
| Cassidy Sean A |
Chief Financial Officer |
• – – |
2023-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
19,125 |
180,572 |
|
- |
|
| Peck Ronald |
Chief Medical Officer |
• – – |
2022-08-12 |
4 |
S |
$68.99 |
$86,794 |
D/D |
(1,258) |
8,154 |
|
40% |
|
| Peck Ronald |
Chief Medical Officer |
• – – |
2022-08-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,010 |
9,412 |
|
- |
|
174 Records found
|
|
Page 1 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.77 (2.44%) 
